Kura Oncology, Inc. (KURA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
$11.56+1.49%
Close 2026-09-14 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
Research Workspace
Put KURA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisManagement screens weak on capital allocation, earnings delivery.
View ManagementThis stock is volatile — it swings about 2% on a typical day and fell roughly 39% in its worst 12-month stretch.
View RiskKura Oncology's growth depends on broadening ziftomenib opportunities across the AML treatment continuum. Revenue growth has been steady, with the latest quarter beating expectations. KURA trades at 13× price-to-sales, slightly above the peer median of 12×. This suggests the price is roughly in line with the growth forecast. A specific risk is the 38% probability of a miss in the next quarter. Peer multiples imply a price about 39% above where it trades. Our read remains intact.
Trailing returns as of 2026-09-14. KURA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering KURA (as of Sep 2026).
Based on 7 Wall Street analysts offering 12-month price targets for KURA in the last 4 months.
Continue this research
Compare KURA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| KURA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put KURA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Commercialize KOMZIFTI
Reiteration of stock rating indicates confidence in launch progress.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $11.56
The last 12 months of price, then the range of analyst 12-month targets from today’s $11.56.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Broaden ziftomenib opportunity across AML treatment continuum
New data on ziftomenib resistance supports broader treatment opportunities.
Advances: Broaden ziftomenib opportunity across AML treatment continuum
Long-term results support ziftomenib's potential in AML.
Advances: Advance darlifarnib as precision combination platform in solid tumors
Updated strategy for darlifarnib supports growth in solid tumors.
Advances: Advance darlifarnib as precision combination platform in solid tumors
Phase 1a data indicates progress in cancer drug combination.
Advances: Advance darlifarnib as precision combination platform in solid tumors
Tumor shrinkage reported indicates strong efficacy in trials.